STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPIX
  4. [Form 4] CUMBERLAND PHARMACEUTICALS INC Insider Trading Activity

Cumberland Pharmaceuticals (CPIX) director reports 2025 10b5-1 buys

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cumberland Pharmaceuticals director Caroline Young reported a series of small open‑market purchases of the company’s common stock in December 2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows daily acquisitions ranging from $2.24 to $4.32 per share between 12/01/2025 and 12/31/2025, each coded as transaction type “L.”

After the final reported purchase on 12/31/2025 at $3.91 per share, Young beneficially owned 33,309 shares of Cumberland common stock in direct form. A footnote explains that the purchases occurred automatically under a Rule 10b5-1 plan adopted on November 14, 2024, indicating these trades were scheduled in advance.

Positive

  • None.

Negative

  • None.
Insider Young Caroline
Role Director
Type Security Shares Price Value
L Common Stock 5 $3.91 $19.55
L Common Stock 2 $3.94 $7.88
L Common Stock 2 $4.01 $8.02
L Common Stock 2 $4.21 $8.42
L Common Stock 2 $4.26 $8.52
L Common Stock 2 $4.13 $8.26
L Common Stock 2 $4.32 $8.64
L Common Stock 2 $4.19 $8.38
L Common Stock 3 $4.19 $12.57
L Common Stock 3 $3.65 $10.95
L Common Stock 3 $3.27 $9.81
L Common Stock 3 $2.82 $8.46
L Common Stock 3 $2.50 $7.50
L Common Stock 3 $2.56 $7.68
L Common Stock 3 $2.60 $7.80
L Common Stock 3 $2.32 $6.96
L Common Stock 3 $2.40 $7.20
L Common Stock 4 $2.34 $9.36
L Common Stock 4 $2.27 $9.08
L Common Stock 4 $2.25 $9.00
L Common Stock 4 $2.24 $8.96
L Common Stock 4 $2.36 $9.44
Holdings After Transaction: Common Stock — 33,309 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Young Caroline
(Last) (First) (Middle)
1600 WEST END AVENUE
SUITE 1300
(Street)
NASHVILLE TN 37203
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/01/2025 L V 4(1) A $2.36 33,247 D
Common Stock 12/02/2025 L V 4(1) A $2.24 33,251 D
Common Stock 12/03/2025 L V 4(1) A $2.25 33,255 D
Common Stock 12/04/2025 L V 4(1) A $2.27 33,259 D
Common Stock 12/05/2025 L V 4(1) A $2.34 33,263 D
Common Stock 12/08/2025 L V 3(1) A $2.4 33,266 D
Common Stock 12/09/2025 L V 3(1) A $2.32 33,269 D
Common Stock 12/10/2025 L V 3(1) A $2.6 33,272 D
Common Stock 12/11/2025 L V 3(1) A $2.56 33,275 D
Common Stock 12/12/2025 L V 3(1) A $2.5 33,278 D
Common Stock 12/15/2025 L V 3(1) A $2.82 33,281 D
Common Stock 12/16/2025 L V 3(1) A $3.27 33,284 D
Common Stock 12/17/2025 L V 3(1) A $3.65 33,287 D
Common Stock 12/18/2025 L V 3(1) A $4.19 33,290 D
Common Stock 12/19/2025 L V 2(1) A $4.19 33,292 D
Common Stock 12/22/2025 L V 2(1) A $4.32 33,294 D
Common Stock 12/23/2025 L V 2(1) A $4.13 33,296 D
Common Stock 12/24/2025 L V 2(1) A $4.26 33,298 D
Common Stock 12/26/2025 L V 2(1) A $4.21 33,300 D
Common Stock 12/29/2025 L V 2(1) A $4.01 33,302 D
Common Stock 12/30/2025 L V 2(1) A $3.94 33,304 D
Common Stock 12/31/2025 L V 5(1) A $3.91 33,309 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.
Remarks:
Caroline Young by /s/ John Hamm as attorney-in-fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What does Cumberland Pharmaceuticals (CPIX) Form 4 report for Caroline Young?

The Form 4 reports that director Caroline Young made a series of open-market purchases of Cumberland Pharmaceuticals common stock in December 2025 under a Rule 10b5-1 trading plan.

How many Cumberland Pharmaceuticals (CPIX) shares does Caroline Young own after these transactions?

Following the final reported transaction on 12/31/2025, Caroline Young beneficially owned 33,309 shares of Cumberland Pharmaceuticals common stock, held directly.

Over what period did the reported CPIX insider purchases occur?

The reported purchases occurred on trading days from 12/01/2025 through 12/31/2025, with small daily acquisitions of Cumberland Pharmaceuticals common stock.

At what prices did Caroline Young purchase Cumberland Pharmaceuticals (CPIX) stock?

The filing shows purchase prices ranging from about $2.24 per share up to $4.32 per share during December 2025.

Were Caroline Young’s CPIX stock trades made under a Rule 10b5-1 plan?

Yes. A footnote states the purchases occurred automatically under a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Is Caroline Young a director or officer of Cumberland Pharmaceuticals (CPIX)?

The filing identifies Caroline Young as a director of Cumberland Pharmaceuticals and not as an officer or 10% owner.